July 19, 2019

Vitrolife A/S
Belinda Dueholm
Regulatory Affairs Specialist
Jens Juuls Vej 20
Viby J, 8260
DENMARK

Re: K182798
Trade/Device Name: KIDScore D3
Regulation Number: 21 CFR 884.6195
Regulation Name: Assisted reproduction embryo image assessment system
Regulatory Class: Class II
Product Code: PBH
Dated: June 17, 2019
Received: June 20, 2019

Dear Belinda Dueholm:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Michael T. Bailey -S

For
Sharon M. Andrews
Assistant Division Director
DHT3B: Division of Reproductive, Gynecology and Urology Devices
OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
Device Name
KIDScore D3

Indications for Use (Describe)

The KIDScore D3 tool provides decision support for prediction of likelihood of embryos developing to the blastocyst stage by scoring them according to their statistical viability.

Adjunctive information provided by KIDScore D3 aids in the selection of embryo(s) for either transfer on Day 3, freezing or continued embryo development when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.

The KIDScore D3 tool is only to be used with the EmbryoScope and EmbryoScope+ timelapse incubator systems.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASTaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”
510(k) Summary – KIDScore D3  
K182798

1. Submitter Information

Submitter: Vitrolife A/S  
Jens Juuls Vej 20  
8260 Viby J  
Denmark

Contact Person: Ms. Belinda Dueholm  
Telephone: +45 7221 7900 (main)  
+45 2076 3707 (direct)

2. Date Prepared: July 19th, 2019

3. Device Information

Proprietary Name: KIDScore D3  
Common Name: Assisted Reproduction Embryo Image Assessment System  
Regulation Number: 21 CFR 884.6195  
Regulation Name: Assisted Reproduction Embryo Image Assessment System  
Product Code: PBH (Embryo Image Assessment System, Assisted Reproduction)  
Regulatory Class: II

4. Predicate Device

Eeva(TM) System, K142147, Auxogyn Inc.

The predicate device has not been subject to any design related recalls.

5. Device Description

The KIDScore D3 decision support tool is an adjunctive algorithm that is designed to support embryologists in their decision about which embryos are suitable for transfer. The tool is an optional accessory to the EmbryoViewer software. It is used in the “Compare & Select” function. The “D3” in the name refers to the use of the algorithm on Day 3 for aiding the embryologist in preparing for transfer of the embryo to the female patient.

KIDScore D3 utilizes the following manually annotated parameters to aid in identifying embryos that are suitable for transfer:

- Pronuclei (number of pronuclei):
- tPNF (time from insemination until pronuclei is fading)
- t2 (time from insemination to complete division to two cells)
- t3 (time from insemination to complete division to three cells)
- t4 (time for insemination to complete division to four cells)
- t5 (time from insemination to complete division to five cells)
- t8 (time from insemination to complete division to eight cells)

The KIDScore D3 assigns scores by comparing the parameters above in embryos to the model criteria, one criterion at a time until the process stops either because the embryo did not pass one of the criteria in the sequence or because the last criterion in the model was reached. From the information available at day three of incubation, the KIDScore D3 divides embryos into five score groups (1-5, as described below):

0 = The embryo is not 2PN
1 = Initial development was too fast or the embryo displayed a direct cleavage from one to three cells
2 = The embryo was slow to develop
3 = Embryo development was irregular and the development pace increased from day two to day three
4 = Embryo development was irregular and the development pace slowed from day two to day three
   and/or
   The number of cells annotated at 66 hours was not as expected
5 = The embryo passed all of the avoidance criteria included in the model.

One or more computers running the EmbryoViewer software may be connected to the ES Server. KIDScore D3 is stored on the computer running the ES Server software. Calculations related to the model in KIDScore D3 are performed on the computer running the ES Server software.

6. Indications for Use

The KIDScore D3 tool provides decision support for prediction of likelihood of embryos developing to the blastocyst stage by scoring them according to their statistical viability.

Adjunctive information provided by KIDScore D3 aids in the selection of embryo(s) for either transfer on Day 3, freezing or continued embryo development when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.

The KIDScore D3 tool is only to be used with the EmbryoScope and EmbryoScope+ timelapse incubator systems.
7. Comparison of Intended Use and Technological Characteristics of the Subject and Predicate Device

### Intended Use

<table>
<thead>
<tr>
<th>Devices</th>
<th>Subject device (K182798) – KIDScore D3</th>
<th>Predicate device (K142147) – Eeva System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications for Use</td>
<td>The KIDScore D3 tool provides decision support for prediction of likelihood of embryos developing to the blastocyst stage by scoring them according to their statistical viability. Adjunctive information provided by KIDScore D3 aids in the selection of embryo(s) for either transfer on Day 3, freezing or continued embryo development when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing. The KIDScore D3 tool is only to be used with the EmbryoScope and EmbryoScope+ time-lapse incubator systems.</td>
<td>The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing. The device may also be used to collect additional time-lapse images until Day 5 of development for embryos not selected for transfer, to allow monitoring of continued embryo development.</td>
</tr>
</tbody>
</table>

The intended use of the subject device is the same as the predicate device – both are intended to provide adjunctive information (decision support) to the embryologist/clinician at Day 3 of culture to aid the user in selecting embryos for transfer/freezing during assisted reproduction procedures.

### Technological Characteristics

<table>
<thead>
<tr>
<th>Device Design</th>
<th>Subject device (KIDScoreD3, K182798)</th>
<th>Predicate device (Eeva System, K142147)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Different: The subject device is a software accessory to be used with the Embryoscope imaging incubator to provide adjunctive information regarding blastocyst quality. The predicate device is a time lapse imaging system to be used in a conventional incubator that utilizes automated image analysis to provide adjunctive blastocyst quality information. These</td>
<td>Integrates the KIDScore D3 decision support tool on the Compare &amp; Select page of the Embryoviewer software present on the Embryoscope and Embryoscope + devices.</td>
<td>Time-lapse system used in conventional incubator with analysis software that automatically identifies embryo development events for use in a blastocyst prediction model</td>
<td></td>
</tr>
</tbody>
</table>
The technological characteristics of the subject and predicate device are different – the subject device has different predictive algorithms for blastocyst quality, and different software and annotation functions. However, different types of safety and effectiveness questions are not raised by these differences in technological characteristics.

**8. Summary of Non-Clinical Performance Testing**

Devices classified under 21 CFR 884.6195 (Assisted Reproduction Embryo Image Assessment System) and product code PBH must address several non-clinical special controls, including software validation, verification, and hazard analysis, an assessment of light exposure and output, simulated use, cleaning and disinfection, package integrity and transit testing, electrical safety and electromagnetic compatibility testing, and prediction algorithm reproducibility.

As the subject device is an optional accessory to the EmbryoViewer software used in the Embryoscope+ incubator (cleared under K173264), some of the special controls do not apply to this submission. The previously cleared version of the Embryoscope+ has met the special controls associated with the majority of the non-clinical performance testing listed above.

In the current submission, the sponsor has addressed the special controls associated with software and algorithm reproducibility. The software verification and validation testing provided in this
submission met the requirements of the FDA Guidance Document, “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices” issued on May 11, 2005. The reproducibility of the prediction algorithm is addressed in the summary of clinical testing described below.

9. Summary of Clinical Testing

Devices classified under 21 CFR 884.6195 (Assisted Reproduction Embryo Image Assessment System) and product code PBH must address a clinical special control to demonstrate reasonable assurance of safety and effectiveness of the device to predict embryo development. The clinical study is described below.

The safety and effectiveness of the KIDScore D3 was investigated in a prospective, single arm, multi-center clinical study conducted at six sites in the United States. This was a non-interventional clinical study where the KIDScore D3 was not used during patient treatment. The purpose of the study was to collect data to evaluate the safety and effectiveness of the KIDScore D3's ability to predict which embryos are most likely to develop to blastocyst stage. This was evaluated by using the KIDScore D3 as adjunct information to traditional morphological grading. Imaging data was collected on embryos cultured to day 5. Embryologists were masked to imaging data and evaluation was only based on morphology and KIDScore D3 scores.

Objective

The study was aimed at analyzing the utilization of established morphology methods with adjunct outcome of an algorithm (KIDScore D3) that provides a score (1 – 5) from timings of morphokinetic events.

Study Design

A double-blinded, multi-center study, designed to evaluate the odds ratios and other measures for outcomes of methodologies used for embryo assessment: day 3 morphology alone and day 3 morphology with KIDScore D3 results as adjunct information.

Selection of Study Data

The data included embryos from 81 patients who underwent in vitro fertilization (IVF) treatment using their own eggs or donor eggs. These data are a subset taken from a total collection of 4152 embryos from 1338 treatments where all sibling embryos have been annotated for the morphokinetic events required by KIDScore D3. These data originate from treatments that were carried out in European IVF clinics, in the period 2009 – 2014.

Primary endpoint

The primary endpoint of the study was to assess the association between the adjunct prediction of blastocyst outcome and the actual blastocyst outcome. The purpose was to determine if KIDScore D3 was informative for embryos graded as an A, B, or C using Day 3 morphology category assignment as compared to the predicate device (Eeva system). For those Good/Fair embryos, the blastocyst Odds Ratio (OR) for the adjunct prediction is required to be statistically significantly greater than 1.
Secondary endpoints

The following calculations were assessed as secondary endpoints:

- Embryo level diagnostic performance measures
  - specificity
  - sensitivity
  - negative predictive value
  - positive predictive value
  - negative likelihood ratio
  - positive likelihood ratio
- Top 2 Embryo analysis
- Treatment level analysis

Results

The study demonstrated that the adjunct use of KIDScore D3 improved the selection of embryos for transfer compared with morphology alone. In the primary endpoint, it was shown that the adjunct use of KIDScore D3 was informative for blastocyst outcome.

The study showed that both the KIDScore D3 and the Eeva system were predictive of blastocyst outcome, with odds ratios greater than one for both systems, as described in the figure below:

<table>
<thead>
<tr>
<th></th>
<th>KIDScore D3</th>
<th>Eeva</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odds ratio</td>
<td>4.13</td>
<td>2.57</td>
</tr>
<tr>
<td>95% CI</td>
<td>3.48 – 4.9</td>
<td>1.88 – 3.51</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

10. Conclusion

The subject and predicate devices have the same intended use and fundamental technological characteristics. The differences in technological characteristics between subject and predicate devices do not raise different questions of safety and effectiveness. The performance data and clinical testing demonstrate that the subject device is substantially equivalent to the predicate device.